Quality of Life of Chronic Kidney Disease Patients With Routine Hemodialysis in General Hospitals in Sleman Yogyakarta

Objective: To elicit quality of life (QOL) of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin, to compare the QOL of CKD patients with routine hemodialysis receiving different erythropoietin, and to explore the change in QOL over six months for patients managed in the hospitals. Methods: A multicenter prospective study was conducted among adult CKD patients in Yogyakarta. QOL was measured using kidney disease quality of life–short form (KDQOL–SFTM) questionnaire and a FACIT fatigue scale questionnaire. CKD patients were divided into 2 groups: those receiving erythropoietin alpha (n=74) and those receiving erythropoietin beta (n=39). Both groups were asked to complete the KDQOL–SFTM questionnaire and a FACIT fatigue scale questionnaire two times in six months range. Results: In the first period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 77.24: 80.21 and 3.35: 3.49 while in the second period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 80.45: 83.95 and 3.45: 3.56. Conclusion: Erythropoietin can improve QOL of CKD patients with routine hemodialysis, while erythropoietin beta gives more improvement, but statistically, it doesn’t different significantly.